Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TRDA
ENTRADA THERAPEUTICS, INC.
NASDAQ
$7.13
▼ DOWN 0.56% (-0.04)

KEY STATISTICS

Market Cap$275.63 M
52w High$16.45
52w Low$5.02
Dividend Yield—
Frequency—
P/E-1.80
Volume341.73K
Shares Out.38.82M

COMPANY

LEADERSHIP

Dipal Doshi
CHIEF EXECUTIVE
Dipal Doshi

COMPENSATION 2026

Salary$635,000
Stock Awards$1,387,428
Incentive Plan Pay$349,250
All Other Comp.$14,000
Total$3,837,737

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 29, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
152

PRICE TARGET

Target High$17.00
Target Low$11.00
Target Median$14.00
Target Consensus$14.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$2.13M
NOV
5
THU

PRICE

$7.13 ▼ DOWN 0.56% (−$0.04)
$7.05$7.13$7.209:34 AM10:38 AM11:42 AM12:47 PM1:51 PM2:55 PM3:59 PM7.13

About Entrada Therapeutics, Inc.

https://www.entradatx.com ↗

Entrada Therapeutics, Inc. develops endosomal escape vehicle therapeutics for neuromuscular diseases, with lead candidates like ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy.

INDUSTRY

Biotechnology

A PRODUCT ENTRADA THERAPEUTICS, INC. IS KNOWN FOR

ENTR-601-44
ENTR-601-44

ENTR-601-44 is Entrada Therapeutics' investigational exon 44 skipping drug candidate for Duchenne muscular dystrophy, using their Endosomal Escape Vehicle platform to deliver oligonucleotides that restore dystrophin production.

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$500K $0 ▼$300K ▲$200K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
71
LISTED HERE
13
RANKED BY POSITION SIZE
VTI
0.00% · 953.7K
XSU.TO
0.01% · 756.1K
SCHA
0.00% · 112.5K
DFMC
0.01% · 77.1K
R2SC.L
0.01% · 70.3K
AVSC
0.02% · 67.8K
PRFZ
0.01% · 27.1K
XRS2.DE
0.01% · 24.7K
GSSC
0.01% · 20.6K
HAPS
0.08% · 19.1K
RSSL
0.01% · 14.0K
BIB
0.01% · 1.4K
KBFR
0.06% · 1.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
70.95%
HOLDERS
171
TOP 12 OF 171 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
5.1M sh · $64.02M
Mpm Asset Management LLC
4.4M sh · $25.41M
5am Venture Management, LLC
4.3M sh · $24.69M
Blackrock, Inc.
2.6M sh · $19.01M
Tcg Crossover Management, LLC
2.3M sh · $28.87M
Merck & Co., Inc.
1.7M sh · $12.8M
Blackrock Inc.
1.7M sh · $24.14M
Vanguard Group Inc
1.6M sh · $16.78M
Bioimpact Capital LLC
1.3M sh · $9.22M
Wellington Management Group Llp
1.0M sh · $10.74M
Millennium Management LLC
836.6K sh · $4.85M
Stepstone Group LP
761.3K sh · $5.6M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
MPM BIOVENTURES 2018, L.P.
Sale · 29.1K shares
2026-09-01
★
10 PERCENT OWNER
MPM BIOVENTURES 2018, L.P.
Sale · 25.1K shares
2026-09-02
★
10 PERCENT OWNER
MPM BIOVENTURES 2018, L.P.
Sale · 32.3K shares
2026-09-03
★
10 PERCENT OWNER
MPM BioVentures 2014, L.P.
Sale · 29.1K shares
2026-09-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
NEUTRAL 1
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY HC Wainwright & Co. NEUTRAL Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ACHV$8.52COMPARE
ALLO$1.98COMPARE
CAPR$9.49COMPARE
AVIR$5.87COMPARE
ARCT$15.92COMPARE
SGMT$10.84COMPARE
VNDA$5.41COMPARE
VYGR$3.49COMPARE